RFK Jr drives pharma to 15-year low

On a losing streak - and then comes RFK

The pharma sector has been facing a growing number of uncertainties which are increasingly getting reflected in biopharma's collapsing multiples. Generalists were already abandoning the sector, as evidenced by 9 straight weeks of HC sector underperformance even before this week's RFK Jr news. Let's have a look at the disaster sector of 2024.